PREMIR Page References

  1. How Common Is Breast Cancer?: Breast Cancer Statistics. (n.d.). Retrieved from
  2. Kerlikowske K;Zhu W;Hubbard RA;Geller B;Dittus K;Braithwaite D;Wernli KJ;Miglioretti DL;O'Meara ES; ;. (n.d.). Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy. Retrieved from
  3. Jacobi, C. E., Jonker, M. A., Nagelkerke, N. J., Houwelingen, J. C., & Bock, G. H. (2003, July 01). Prevalence of family histories of breast cancer in the general population and the incidence of related seeking of health care. Retrieved from
  4. Key facts and figures. (2020). doi:10.1787/a900334c-en
  5. FJ;, L. J. (n.d.). Common Genetic Variation and Breast Cancer Risk-Past, Present, and Future. Retrieved from
  6. Breast Cancer Risk Factors: Family History. (2021, April 21). Retrieved from
  7. DeSantis, C. E., Ma, J., Gaudet, M. M., Newman, L. A., Miller, K. D., Sauer, A. G., . . . Siegel, R. L. (2019, October 02). Breast cancer statistics, 2019. Retrieved from
  8. Breast Cancer Risk in American Women. (n.d.). Retrieved from
  9. What Does It Mean to Have Dense Breasts? (2020, January 14). Retrieved from
  10. P;, N. S. (n.d.). An overview of mammographic density and its association with breast cancer. Retrieved from
  11. Hereditary Breast Cancer and BRCA Genes. (2019, April 05). Retrieved from
  12. BRCA Gene Mutations: Cancer Risk and Genetic Testing Fact Sheet. (n.d.). Retrieved from
  13. Mehrgou, A., & Akouchekian, M. (2016, May 15). The importance of BRCA1 and BRCA2 genes mutations in breast cancer development. Retrieved from breast cancer, which is,15% of ovarian cancer cases.
  14. Daly, M. B., Pilarski, R., Yurgelun, M. B., Berry, M. P., Buys, S. S., Dickson, P., . . . Darlow, S. D. (2020, April 01). NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. Retrieved from
  15. Hyperplasia of the Breast (Ductal or Lobular). (n.d.). Retrieved from
  16. Ductal Carcinoma In Situ: Symptoms, Diagnosis, and Treatment. (2019, March 09). Retrieved from
  17. Kerlikowske, K. (2010). Epidemiology of ductal carcinoma in situ. Retrieved from it is rarely clinically,cases (2–4).
  18. Diagnosis of DCIS. (2018, February 20). Retrieved from
  19. Lobular Carcinoma In Situ (LCIS). (2019, March 09). Retrieved from
  20. LCIS and Breast Cancer Risk. (2016, February 18). Retrieved from estimate is that the,over the next 15 years.
  21. Symptoms and Diagnosis of LCIS. (2015, September 30). Retrieved from
  22. King, T. A., Pilewskie, M., Muhsen, S., Patil, S., Mautner, S. K., Park, A., . . . Morrow, M. (n.d.). Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. Retrieved from

Technology Page References

  1. Kosaka, N., Yoshioka, Y., Fujita, Y., & Ochiya, T. (2016, April 01). Versatile roles of extracellular vesicles in cancer. Retrieved from
  2. Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., . . . Golub, T. R. (n.d.). MicroRNA expression profiles classify human cancers. Retrieved from
  3. Calin, G. A., & Croce, C. M. (n.d.). MicroRNA signatures in human cancers. Retrieved from
  4. Galvão-Lima, L. J., Morais, A. H., Valentim, R. A., & Barreto, E. J. (2021, February 16). MiRNAs as biomarkers for early cancer detection and their application in the development of new diagnostic tools. Retrieved from
  5. Jang, J. Y., Kim, Y. S., Kang, K. N., Kim, K. H., Park, Y. J., & Kim, C. W. (2021, February). Multiple microRNAs as biomarkers for early breast cancer diagnosis. Retrieved from
  6. PubMed_((miRNA) OR (micro RNA)) AND ((cancer) OR (tumor)) AND ((early stage) OR (early-stage))_2000_2020
  7. PubMed_((cfDNA) OR (cell-free DNA)) AND ((cancer) OR (tumor)) AND ((early stage) OR (early-stage))_2000_2020
  8. Gahlawat, A. W., Lenhardt, J., Witte, T., Keitel, D., Kaufhold, A., Maass, K. K., . . . Schott, S. (2019). Evaluation of Storage Tubes for Combined Analysis of Circulating Nucleic Acids in Liquid Biopsies. International Journal of Molecular Sciences, 20(3), 704. doi:10.3390/ijms20030704
  9. Mafi, M. (2018). Review of "Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies". doi:10.14322/publons.r2313482
  10. Volik, S., Alcaide, M., Morin, R. D., & Collins, C. (2016). Cell-free DNA (cfDNA): Clinical Significance and Utility in Cancer Shaped By Emerging Technologies. Molecular Cancer Research, 14(10), 898-908. doi:10.1158/1541-7786.mcr-16-0044

We use cookies to provide you with a greater online experience. By using our sites, you agree to our use of cookies. See our cookie policy.